Asana Biosciences, LLC

Ikaria Inc.

Libertas Bio, Inc.

Helen Usansky

Louis Denis

Navnit Hargovindas Shah

Wantanee Phuapradit

Sandeep Gupta

Ashish Chatterji

Paras Jariwala

Harpreet Sandhu

Khurram Jamil

Niranjan Rao

David Zammit

Aruna Railkar

Sarper Toker

Embodiments of the disclosure relate generally to formulations, methods of treatment, kits, and dosage forms for treating inflammatory disorders, including topic dermatitis, cancer, the formulations comprising an active pharmaceutical ingredient. The formulation provided comprises granules, wherein the granules comprise: micronized active ingredient; one or more granulation binders; one or more fillers; one or more disintegrants; and one or more antioxidants. In one embodiment, the methods of treatment include orally administering the active ingredient to a subject suffering from atopic dermatitis, where the active ingredient, is in an amount of about 20 mg to about 80 mg.

Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient

Embodiments of the disclosure relate generally to formulations, methods, kits, and dosage forms for improved stability of an active pharmaceutical ingredient, wherein the active ingredient comprises a compound of the formula: wherein X is N, Y is H or optionally substituted C-Calkyl; Ris morpholine optionally substituted with by C-Calkyl; Ris C-Calkyl optionally substituted by one or more F; Ris halogen; and Ris wherein Ris H, C-Calkyl, halogen, CN or CF; Ris H or halogen; Ris H, halogen or C-Calkyl; and Ris H, C-Calkyl, (C-Calkyl)-NH; and, pharmaceutically acceptable salts and free bases thereof, wherein the active ingredient remains in substantially amorphous form after storage of the pharmaceutical formulation for a predetermined time and conditions. In one embodiment the formulations, methods, kits and dosage forms comprising the active pharmaceutical ingredient with improved stability can be used in the treatment of a condition characterized by the dysregulation of one of both of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways.

Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient

The present invention is directed to dosing regimens for the administration of carbon monoxide in the treatment of various indications as well as methods for enhancing organ function following transplant thereof.

Dosing regimens and methods of treatment using carbon monoxide

Growing community of inventors

Hillsborough, NJ, United States of America

Helen Usansky